Enzyme-linked immunoassays

To determine circulating levels of potential disease candidates, plasma samples were obtained from patients with CTEPH (n = 27) and compared with those from age- and sex-matched patients with PAH (n = 23) or healthy control individuals (n = 6), and examined with the use of ELISA. To determine levels of potential disease candidates in patients with CTEPH before and after PEA, plasma samples from 18 CTEPH patients were analyzed. Venous blood was collected on the day of surgery and at 12-month follow-up. The baseline characteristics of patients examined by ELISA are included in Supplemental Table 1. Plasma levels of human transforming growth factor-β-induced protein (TGFBI) (OriGene {"type":"entrez-nucleotide","attrs":{"text":"EA100707","term_id":"145032623","term_text":"EA100707"}}EA100707; detection limit: <10 pg/mL), follistatin-like 3 (FSTL3) (OriGene {"type":"entrez-nucleotide","attrs":{"text":"EA100552","term_id":"145032468","term_text":"EA100552"}}EA100552; detection limit: <10 pg/mL), stanniocalcin 2 (STC2) (Abcam ab222880; calculated minimal detectable dose: 0.95 ng/mL), and transgelin (TAGLN) (LS Biosciences LS-{"type":"entrez-nucleotide","attrs":{"text":"F22522","term_id":"2061698","term_text":"F22522"}}F22522; detection limit: <3.75 ng/mL) were determined with the use of specific ELISAs.